MONOCLONAL ANTI-SH3GL1 (C-TERMINAL) ANTI

Application

Monoclonal Anti-SH3GL1 (C-terminal) antibody produced in mouse has been used in immunoblotting and flow cytometry.

Biochem/physiol Actions

SH3GL1 is involved in several brain tumors, such as glioma, where its levels were increased in proportion to the tumor progression. In cells generated from children malignant brain tumor medulloblastoma (MB), SH3GL1 expression was found to be regulated by the miRNA, miR-218.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Monoclonal Anti-SH3GL1 (C-terminal) (mouse IgG2b isotype) is derived from the hybridoma Ep2.17 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice. SH3GL1 (SH3-domain GRB2-like 1), also known as endophilin-A2, is a member of the endophilin family of Src homology 3 (SH3) domain-containing proteins. The SH3 domain drives protein-protein interactions through binding to proline-rich ligands. The SH3GL proteins have a novel N-terminal segment, and a peculiar tissue distribution: SH3GL1 is ubiquitous, SH3GL2 located in the brain, and SH3GL3 in brain and testis.

Immunogen

a synthetic peptide corresponding to a sequence at the C-terminal region of human SH3GL1

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.